Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives Consensus Rating of “Moderate Buy” from Analysts

Centessa Pharmaceuticals plc (NASDAQ:CNTA) has earned an average recommendation of “Moderate Buy” from the seven analysts that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $10.00.

Separately, BMO Capital Markets reiterated an “outperform” rating and set a $15.00 price target on shares of Centessa Pharmaceuticals in a research report on Monday, April 1st.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 51,160 shares of the business’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $11.88, for a total value of $607,780.80. Following the transaction, the insider now directly owns 71,525 shares of the company’s stock, valued at approximately $849,717. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, insider Karen M. Anderson sold 51,160 shares of the firm’s stock in a transaction on Monday, March 25th. The stock was sold at an average price of $11.88, for a total value of $607,780.80. Following the completion of the transaction, the insider now owns 71,525 shares in the company, valued at $849,717. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Harris Rotman sold 4,267 shares of the firm’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $8.10, for a total value of $34,562.70. Following the completion of the transaction, the senior vice president now owns 62,625 shares of the company’s stock, valued at approximately $507,262.50. The disclosure for this sale can be found here. 11.54% of the stock is owned by insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Quarry LP bought a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at approximately $48,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Centessa Pharmaceuticals by 371.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,394 shares of the company’s stock valued at $51,000 after acquiring an additional 5,037 shares during the last quarter. Jump Financial LLC bought a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at approximately $114,000. Trexquant Investment LP bought a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at approximately $114,000. Finally, Rathbones Group PLC bought a new stake in shares of Centessa Pharmaceuticals in the 3rd quarter valued at approximately $203,000. 82.01% of the stock is owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Trading Down 5.6 %

Shares of NASDAQ CNTA opened at $8.93 on Friday. The business has a fifty day moving average price of $10.90 and a 200 day moving average price of $8.51. The company has a debt-to-equity ratio of 0.32, a current ratio of 8.00 and a quick ratio of 8.00. Centessa Pharmaceuticals has a 1-year low of $3.96 and a 1-year high of $12.45. The stock has a market capitalization of $895.77 million, a P/E ratio of -5.69 and a beta of 1.38.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. The firm had revenue of $6.85 million during the quarter. Equities research analysts expect that Centessa Pharmaceuticals will post -1.83 EPS for the current fiscal year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.